Livia Guadalupi, Georgia Mandolesi, Valentina Vanni, Sara Balletta, Silvia Caioli, Anto Pavlovic, Francesca De Vito, Diego Fresegna, Krizia Sanna, Laura Vitiello, Monica Nencini, Alice Tartacca, Fabrizio Mariani, Valentina Rovella, Sven Schippling, Iris Ruf, Ludovic Collin, Diego Centonze, Alessandra Musella
The endocannabinoid system (ECS) is critically involved in the pathophysiology of Multiple Sclerosis (MS), a neuroinflammatory and neurodegenerative disease of the central nervous system (CNS). Over the past decade, researchers have extensively studied the neuroprotective and anti-inflammatory effects of the ECS. Inhibiting the degradation of the endocannabinoid 2-arachidonoylglycerol (2-AG) has emerged as a promising strategy to mitigate brain damage in MS. In this study, we investigated the effects of a novel reversible MAGL inhibitor (MAGLi 432) on C57/BL6 female mice with experimental autoimmune encephalomyelitis (EAE), a model of MS...
April 1, 2024: Neuropharmacology